France will begin partially reimbursing the anti-obesity drugs Wegovy and Mounjaro for patients with severe obesity starting mid-June 2026 [3].
This move expands access to high-cost medical treatments for a critical public health issue, shifting the financial burden of weight-loss medication from individuals to the state.
Health Minister Stéphanie Rist said the decision on May 28, 2026 [4]. Under the new policy, the Assurance maladie (Sécurité sociale) will cover approximately 65% of the cost for these medications [1]. The reimbursement is not universal, and it is specifically reserved for patients diagnosed with the most severe cases of obesity [1].
The drugs in question, Wegovy (semaglutide) and Mounjaro (tirzepatide), have gained global prominence for their effectiveness in weight reduction. However, their high price points have historically limited access to wealthy patients or those with private insurance.
Government estimates suggest the program will cost the Social Security system approximately 100 million euros per year [2]. This expenditure reflects the government's effort to balance the immediate need for severe obesity treatment with the long-term sustainability of the national healthcare budget.
Officials said the goal is to provide essential treatment to those in need while managing the high cost of the drugs [2]. The implementation of the reimbursement process is expected to be finalized by the middle of next month [3].
“France will begin partially reimbursing the anti-obesity drugs Wegovy and Mounjaro for patients with severe obesity”
By integrating GLP-1 receptor agonists into the national reimbursement scheme, France is acknowledging obesity as a chronic disease requiring state-funded medical intervention. The strict limitation to 'severe' cases and a 65% coverage cap suggest a cautious fiscal approach to prevent a budget surge, as these drugs are expensive and highly sought after.
